Two Sigma Advisers LP raised its position in LivaNova PLC (NASDAQ:LIVN - Free Report) by 148.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 214,545 shares of the company's stock after buying an additional 128,200 shares during the period. Two Sigma Advisers LP owned approximately 0.40% of LivaNova worth $9,936,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. boosted its position in LivaNova by 17.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock valued at $70,000 after buying an additional 219 shares during the last quarter. Summit Investment Advisors Inc. boosted its position in LivaNova by 1.7% in the 4th quarter. Summit Investment Advisors Inc. now owns 16,846 shares of the company's stock valued at $780,000 after buying an additional 289 shares during the last quarter. Xponance Inc. boosted its position in LivaNova by 6.1% in the 4th quarter. Xponance Inc. now owns 7,762 shares of the company's stock valued at $359,000 after buying an additional 445 shares during the last quarter. Mariner LLC boosted its position in LivaNova by 8.4% in the 4th quarter. Mariner LLC now owns 5,741 shares of the company's stock valued at $266,000 after buying an additional 446 shares during the last quarter. Finally, Invesco Ltd. boosted its position in LivaNova by 0.6% in the 4th quarter. Invesco Ltd. now owns 111,374 shares of the company's stock valued at $5,158,000 after buying an additional 667 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several equities analysts have recently commented on the stock. Wall Street Zen cut shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 8th. Mizuho reduced their price target on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a research report on Wednesday, February 26th. Needham & Company LLC reaffirmed a "buy" rating and set a $64.00 price target on shares of LivaNova in a research report on Tuesday, May 13th. Barclays reduced their price target on shares of LivaNova from $56.00 to $55.00 and set an "equal weight" rating on the stock in a research report on Thursday, May 8th. Finally, Robert W. Baird increased their price target on shares of LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, LivaNova currently has an average rating of "Buy" and a consensus target price of $59.29.
View Our Latest Analysis on LIVN
LivaNova Stock Performance
Shares of NASDAQ:LIVN traded down $0.88 during trading hours on Wednesday, hitting $43.14. The stock had a trading volume of 90,597 shares, compared to its average volume of 649,549. The stock's fifty day simple moving average is $38.86 and its 200 day simple moving average is $44.48. LivaNova PLC has a 1-year low of $32.48 and a 1-year high of $61.94. The firm has a market capitalization of $2.35 billion, a price-to-earnings ratio of 102.84 and a beta of 0.84. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37.
About LivaNova
(
Free Report)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Featured Stories
Before you consider LivaNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LivaNova wasn't on the list.
While LivaNova currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
